Prevail Therapeutics

/Prevail Therapeutics

We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases.

Symbol

Price Range
$16.00 - $18.00

Final Shares
7,353,000

Anticipated Date
June 20, 2019

Underwriters

This offering is no longer available

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange